Index RUT P/E 6000.00 EPS (ttm) 0.00 Insider Own 2.07% Shs Outstand 446.82M Perf Week 3.63%
Market Cap 2.64B Forward P/E 6.67 EPS next Y 0.90 Insider Trans -2.15% Shs Float 430.38M Perf Month -5.36%
Income 16.00M PEG 1200.00 EPS next Q 0.18 Inst Own 83.46% Short Float 1.53% Perf Quarter -4.91%
Sales 6.88B P/S 0.38 EPS this Y 761.11% Inst Trans 0.82% Short Ratio 2.28 Perf Half Y 3.81%
Book/sh 16.74 P/B 0.36 EPS next Y 16.13% ROA 0.02% Short Interest 6.59M Perf Year 0.33%
Cash/sh - P/C - EPS next 5Y 5.00% ROE 0.18% 52W Range 4.51 - 6.93 Perf YTD -10.18%
Dividend Est. - P/FCF 4.42 EPS past 5Y -7.62% ROI 0.18% 52W High -13.42% Beta 1.08
Dividend TTM - Quick Ratio - Sales past 5Y -2.46% Gross Margin - 52W Low 33.04% ATR (14) 0.15
Dividend Ex-Date Oct 08, 2008 Current Ratio - EPS Y/Y TTM -99.45% Oper. Margin 5.05% RSI (14) 44.72 Volatility 2.24% 2.36%
Employees 2700 Debt/Eq 0.22 Sales Y/Y TTM -8.41% Profit Margin 0.23% Recom 3.00 Target Price 7.00
Option/Short Yes / Yes LT Debt/Eq 0.22 EPS Q/Q -235.62% Payout 0.00% Rel Volume 1.25 Prev Close 6.10
Sales Surprise - EPS Surprise -368.42% Sales Q/Q -21.85% Earnings May 01 AMC Avg Volume 2.89M Price 6.00
SMA20 -2.18% SMA50 -2.95% SMA200 -0.84% Trades
Volume 3,779,111 Change -1.64%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-23-16 Resumed Wells Fargo
Market Perform
May-05-16 Reiterated Compass Point
Buy
$5.50 → $5.25
Feb-08-16 Reiterated Compass Point
Buy
$7.50 → $5.50
Nov-17-15 Initiated Goldman
Neutral
$5
Nov-04-15 Downgrade UBS
Neutral → Sell
$5.25 → $4.25
Sep-08-15 Reiterated UBS
Neutral
$8.50 → $5.25
Aug-10-15 Reiterated Compass Point
Buy
$12 → $7.50
Aug-06-15 Downgrade Raymond James
Strong Buy → Outperform
Aug-05-15 Upgrade Macquarie
Underperform → Neutral
Jul-20-15 Reiterated UBS
Neutral
$10 → $8.50
May-28-15 Upgrade Morgan Stanley
Underweight → Equal-Weight
May-07-15 Downgrade Macquarie
Outperform → Underperform
$12 → $7
May-06-15 Reiterated Jefferies
Buy
$10 → $12
May-05-15 Downgrade Morgan Stanley
Equal-Weight → Underweight
$8.50 → $8
Apr-30-15 Upgrade Compass Point
Neutral → Buy
Nov-06-14 Downgrade Compass Point
Buy → Neutral
Jul-31-14 Reiterated Compass Point
Buy
$23 → $16.50
Mar-20-14 Reiterated UBS
Buy
$18 → $20
Jan-07-14 Initiated Compass Point
Buy
$22
Jul-18-12 Initiated UBS
Neutral
$5.50
Show Previous Ratings
Apr-20-24 01:30PM
Apr-07-24 12:45PM
Apr-04-24 04:15PM
Mar-30-24 06:50AM
Mar-12-24 08:55AM
09:13AM
Loading…
Feb-23-24 09:13AM
Feb-22-24 11:13PM
(Thomson Reuters StreetEvents)
02:45PM
Feb-21-24 05:59PM
(Associated Press Finance)
04:54PM
04:15PM
Feb-13-24 08:30AM
Jan-22-24 04:15PM
Nov-11-23 09:33AM
Nov-09-23 10:55PM
(Thomson Reuters StreetEvents) -8.17%
02:00PM
Loading…
02:00PM
Nov-08-23 06:04PM
05:36PM
(Associated Press Finance)
04:15PM
Oct-25-23 04:15PM
Oct-12-23 04:15PM
Oct-11-23 12:10PM
Oct-09-23 09:00AM
Sep-06-23 04:48PM
Aug-09-23 11:58PM
(Thomson Reuters StreetEvents)
12:30PM
Aug-08-23 06:23PM
(Associated Press Finance)
04:15PM
Jul-31-23 06:11PM
06:09PM
04:15PM
Loading…
Jul-06-23 04:15PM
09:09AM
Jun-22-23 05:14PM
05:11PM
05:06PM
Jun-21-23 08:00PM
May-18-23 05:47PM
May-04-23 11:30PM
(Thomson Reuters StreetEvents) -13.53%
04:09PM
03:30PM
May-03-23 06:36PM
04:15PM
Apr-26-23 08:00PM
Apr-06-23 04:33PM
Mar-27-23 12:07PM
Mar-17-23 05:54PM
11:11AM
Mar-01-23 04:15PM
Feb-28-23 11:45AM
Feb-16-23 04:10PM
Feb-13-23 07:58AM
12:47AM
Feb-10-23 01:43PM
Feb-08-23 02:12PM
Feb-07-23 01:30PM
Feb-06-23 04:20PM
04:10PM
Jan-27-23 07:56AM
Jan-06-23 04:15PM
Dec-01-22 06:56AM
Nov-30-22 02:47PM
Nov-10-22 03:26PM
Nov-09-22 05:07AM
Nov-02-22 12:00PM
Nov-01-22 04:15PM
Oct-11-22 09:27PM
Oct-07-22 04:15PM
Oct-04-22 07:00AM
Sep-21-22 04:15PM
Aug-22-22 07:00AM
Aug-20-22 08:52AM
Aug-02-22 04:30PM
Aug-01-22 04:30PM
Jul-22-22 06:45AM
Jul-08-22 07:15AM
Jun-27-22 07:14AM
May-27-22 10:15AM
(American City Business Journals)
May-20-22 07:30AM
May-11-22 06:35AM
May-04-22 01:00PM
May-03-22 04:30PM
May-02-22 04:15PM
Apr-15-22 09:59AM
Apr-05-22 04:45PM
Mar-23-22 06:30PM
Mar-14-22 12:05PM
07:00AM
Feb-17-22 04:15AM
Feb-16-22 11:10AM
11:08AM
11:06AM
11:04AM
11:02AM
11:00AM
10:58AM
10:56AM
10:54AM
10:52AM
10:50AM
10:48AM
Genworth Financial, Inc. engages in offering mortgage and long-term care insurance products. It operates through the following segments: Enact, Long-Term Care Insurance, Life and Annuities, and Corporate and Other. The Enact segment refers to Enact Holdings that offers private mortgage insurance products. The Long-Term Care Insurance segment offers long-term care insurance products in the United States. The Life and Annuities segment focuses on protection and retirement income products. The Corporate and Other segment includes debt financing expenses. The company was founded in 1871 and is headquartered in Richmond, VA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McInerney Thomas J President and CEO; Director Dec 04 '23 Sale 6.18 200,000 1,235,400 3,270,010 Dec 05 04:15 PM McInerney Thomas J President and CEO; Director Aug 11 '23 Sale 6.01 200,000 1,201,200 3,470,010 Aug 14 05:01 PM McInerney Thomas J President and CEO; Director May 22 '23 Sale 5.52 125,000 690,500 4,649,974 May 23 05:00 PM
Index - P/E 10.70 EPS (ttm) 0.45 Insider Own 28.05% Shs Outstand 47.65M Perf Week -6.58%
Market Cap 232.85M Forward P/E 28.41 EPS next Y 0.17 Insider Trans -0.82% Shs Float 34.68M Perf Month -13.60%
Income 21.59M PEG - EPS next Q -0.22 Inst Own 54.87% Short Float 9.59% Perf Quarter -3.40%
Sales 235.64M P/S 0.99 EPS this Y -42.22% Inst Trans -2.11% Short Ratio 5.74 Perf Half Y 109.09%
Book/sh 1.12 P/B 4.31 EPS next Y -34.62% ROA 9.54% Short Interest 3.33M Perf Year 73.74%
Cash/sh 1.99 P/C 2.43 EPS next 5Y - ROE 57.54% 52W Range 2.13 - 7.73 Perf YTD 11.55%
Dividend Est. - P/FCF 8.67 EPS past 5Y - ROI 17.12% 52W High -37.52% Beta 1.31
Dividend TTM - Quick Ratio 1.50 Sales past 5Y -0.59% Gross Margin 73.40% 52W Low 126.76% ATR (14) 0.34
Dividend Ex-Date - Current Ratio 1.57 EPS Y/Y TTM 15796.55% Oper. Margin 14.12% RSI (14) 39.33 Volatility 5.77% 5.79%
Employees 185 Debt/Eq 2.09 Sales Y/Y TTM 3.34% Profit Margin 9.16% Recom 3.00 Target Price 4.33
Option/Short Yes / Yes LT Debt/Eq 1.36 EPS Q/Q 308.66% Payout 0.00% Rel Volume 0.54 Prev Close 5.13
Sales Surprise -1.84% EPS Surprise -13.33% Sales Q/Q 9.90% Earnings May 02 AMC Avg Volume 579.37K Price 4.83
SMA20 -9.91% SMA50 -14.42% SMA200 16.39% Trades
Volume 365,894 Change -5.85%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-28-21 Upgrade Citigroup
Neutral → Buy
$11
Jun-25-20 Resumed BofA/Merrill
Underperform
$9
Oct-08-19 Downgrade Goldman
Neutral → Sell
$24 → $8
May-10-19 Downgrade Citigroup
Buy → Neutral
$24
May-10-19 Downgrade Cantor Fitzgerald
Overweight → Neutral
$57 → $20
Jan-17-19 Initiated Leerink Partners
Mkt Perform
$21
Jan-03-19 Downgrade Guggenheim
Buy → Neutral
Nov-19-18 Upgrade Goldman
Sell → Neutral
Nov-02-18 Downgrade JP Morgan
Neutral → Underweight
Nov-02-18 Downgrade BofA/Merrill
Buy → Underperform
Oct-01-18 Initiated Cantor Fitzgerald
Overweight
$75
Sep-17-18 Initiated Goldman
Sell
$42
May-11-18 Reiterated Stifel
Buy
$95 → $87
Nov-10-17 Reiterated RBC Capital Mkts
Sector Perform
$92 → $108
Nov-10-17 Reiterated Citigroup
Buy
$156 → $164
Oct-02-17 Reiterated Stifel
Buy
$110 → $130
Sep-11-17 Reiterated Credit Suisse
Outperform
$118 → $136
Jul-10-17 Resumed Leerink Partners
Outperform
$115
Jun-06-17 Reiterated RBC Capital Mkts
Sector Perform
$60 → $88
May-25-17 Reiterated RBC Capital Mkts
Sector Perform
$40 → $60
Show Previous Ratings
Apr-18-24 04:15PM
Apr-11-24 06:00PM
Apr-03-24 05:30PM
Mar-22-24 09:25AM
Mar-20-24 08:30AM
08:29AM
Loading…
Mar-02-24 08:29AM
Mar-01-24 09:55AM
(Thomson Reuters StreetEvents) -5.31%
09:40AM
09:39AM
Feb-29-24 04:41PM
04:40PM
(Associated Press Finance)
04:05PM
Feb-27-24 06:30PM
11:51AM
Feb-22-24 04:10PM
04:10PM
Loading…
Feb-15-24 04:10PM
Feb-13-24 08:30AM
Jan-31-24 12:58PM
Jan-11-24 04:07PM
Jan-06-24 11:02AM
Dec-11-23 08:30AM
Nov-20-23 11:47AM
Nov-06-23 05:15PM
Nov-03-23 12:16PM
09:34AM
(Thomson Reuters StreetEvents)
09:31AM
Nov-02-23 07:42PM
04:47PM
(Associated Press Finance)
04:05PM
Oct-19-23 04:14PM
12:30PM
Loading…
Oct-14-23 12:30PM
Oct-04-23 05:30PM
Sep-22-23 07:57AM
Sep-21-23 04:10PM
Aug-31-23 04:07PM
Aug-08-23 08:30AM
Aug-04-23 12:36PM
09:23AM
(Thomson Reuters StreetEvents)
Aug-03-23 05:17PM
04:05PM
Jul-20-23 04:15PM
Jun-13-23 09:30AM
Jun-06-23 05:03PM
Jun-04-23 09:00AM
May-28-23 10:06AM
May-22-23 11:07AM
May-05-23 05:15PM
12:45PM
09:44AM
(Thomson Reuters StreetEvents)
May-04-23 05:32PM
04:04PM
Apr-20-23 04:15PM
Apr-17-23 06:49AM
Apr-11-23 05:15PM
Mar-14-23 08:30AM
Mar-06-23 09:48AM
Mar-03-23 05:15PM
02:20PM
06:22AM
(Thomson Reuters StreetEvents)
Mar-02-23 04:05PM
Feb-28-23 04:15PM
Feb-19-23 02:05PM
Feb-16-23 04:31PM
Feb-07-23 05:30PM
Feb-01-23 08:30AM
Jan-25-23 06:19AM
Jan-12-23 04:15PM
Jan-11-23 05:30PM
Jan-09-23 08:55AM
Dec-20-22 08:31AM
Dec-15-22 03:39PM
Dec-07-22 06:03PM
Dec-05-22 05:30PM
Dec-01-22 08:36AM
Nov-28-22 09:55AM
Nov-22-22 09:15AM
08:50AM
Nov-21-22 05:25PM
Nov-17-22 09:40AM
Nov-14-22 10:10AM
09:50AM
Nov-11-22 10:20AM
Nov-09-22 10:43AM
06:02AM
Nov-07-22 01:02PM
(Simply Wall St.) +15.50%
Nov-04-22 12:29PM
12:20PM
12:18PM
11:18AM
Nov-03-22 06:45PM
04:05PM
Nov-02-22 05:30PM
Oct-27-22 04:05AM
Oct-20-22 04:15PM
Oct-12-22 09:31AM
Oct-04-22 05:30PM
Sep-21-22 11:35AM
10:15AM
Sep-20-22 04:05PM
Sep-11-22 05:15AM
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
AUERBACH ALAN H President and CEO Jan 03 '24 Sale 4.49 41,396 185,698 6,936,947 Jan 05 06:56 PM NOUGUES MAXIMO F Chief Financial Officer Jan 03 '24 Sale 4.49 15,682 70,348 128,666 Jan 05 06:49 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jan 03 '24 Sale 4.49 12,956 58,119 99,970 Jan 05 07:00 PM HUNT DOUGLAS M See Remarks Jan 03 '24 Sale 4.49 8,358 37,493 103,319 Jan 05 06:42 PM Wong Alvin F Chief Scientific Officer Jan 03 '24 Sale 4.49 7,733 34,689 98,214 Jan 05 07:03 PM Wong Alvin F Chief Scientific Officer Dec 04 '23 Sale 3.76 280 1,053 97,934 Jan 10 04:41 PM MILLER MICHAEL PATRICK Director Nov 07 '23 Sale 2.83 25,000 70,802 43,358 Nov 09 04:19 PM AUERBACH ALAN H President and CEO Jul 03 '23 Sale 3.31 60,698 200,983 6,978,343 Jul 06 07:03 PM NOUGUES MAXIMO F Chief Financial Officer Jul 03 '23 Sale 3.31 14,680 48,608 144,348 Jul 06 07:12 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jul 03 '23 Sale 3.31 12,103 40,075 112,926 Jul 06 07:08 PM HUNT DOUGLAS M See Remarks Jul 03 '23 Sale 3.31 7,809 25,857 111,677 Jul 06 07:06 PM Wong Alvin F Chief Scientific Officer Jul 03 '23 Sale 3.31 6,938 22,973 105,947 Jul 06 07:16 PM Senderowicz Adrian Director Jun 13 '23 Sale 3.45 27,000 93,280 0 Jun 15 09:03 PM WILSON TROY EDWARD Director Jun 13 '23 Sale 3.45 27,000 93,269 350 Jun 15 09:14 PM MOYES JAY M Director Jun 13 '23 Sale 3.45 22,000 75,970 16,322 Jun 15 09:10 PM MILLER MICHAEL PATRICK Director Jun 13 '23 Sale 3.45 13,500 46,630 41,358 Jun 15 08:28 PM Dorval Allison Director Jun 13 '23 Sale 3.45 10,000 34,500 17,000 Jun 15 09:01 PM Stuglik Brian M Director Jun 13 '23 Sale 3.46 9,900 34,252 31,958 Jun 15 09:06 PM Wong Alvin F Chief Scientific Officer Jun 02 '23 Sale 3.45 269 928 112,885 Jun 06 04:36 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
